DarioHealth director buys 14,430 common shares

DarioHealth Corp. director Dennis Matheis purchased 14,430 shares of Common Stock at $6.93 per share on July 23, 2026, under a Securities Purchase Agreement dated July 22, 2026.

Rhea-AI Filing Summary

DarioHealth Corp. director Dennis Matheis purchased 14,430 shares of Common Stock at $6.93 per share on July 23, 2026, under a Securities Purchase Agreement dated July 22, 2026. Earlier, on August 12, 2024, 50 shares of his Series B-2 Preferred Stock automatically converted into 965 post–reverse-split common shares, subject to a 19.99% beneficial ownership blocker, and he beneficially owned 28,596 common shares immediately after that conversion.

Insider Trade Summary

Net Buyer: 14,430 shares

Net Buy 3 txns

Insider Matheis Dennis

Role Director

Bought 14,430 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F3	14,430	$6.93	$100K
Conversion	Series B-2 Preferred Stock	50	$1,000.00	$50K
Conversion	Common Stock F1, F2	965	$19.10	$18K

Holdings After Transaction: Series B-2 Preferred Stock — 0 contracts (Direct); Common Stock — 43,026 shares (Direct)

Footnotes (3)

1. F1. Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.
2. F2. The Reporting Person's 50 shares of Series B-2 Preferred Stock automatically converted into 19,289 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 965 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 28,596 shares of Common Stock immediately following the conversion.
3. F3. The reported shares were acquired pursuant to a Securities Purchase Agreement with the issuer, dated July 22, 2026, at a purchase price of $6.93 per share.

Key Figures

Common shares purchased: 14,430 shares Purchase price: $6.93 per share Preferred shares converted: 50 shares +4 more

7 metrics

Common shares purchased 14,430 shares Common Stock bought by director Dennis Matheis on July 23, 2026

Purchase price $6.93 per share Price under Securities Purchase Agreement dated July 22, 2026

Preferred shares converted 50 shares Series B-2 Preferred Stock automatically converted on August 12, 2024

Common shares from conversion 965 shares Common Stock reported after reverse stock split from conversion of 50 Series B-2 Preferred shares

Beneficial ownership after conversion 28,596 shares Common Stock beneficially owned by Dennis Matheis immediately following August 12, 2024 conversion

Ownership blocker 19.99% Non-waivable beneficial ownership limitation on automatic conversion of Series B Preferred Stock

Series B-2 conversion price $1,000.00 per share Conversion price for Series B-2 Preferred Stock

Key Terms

Series B-2 Preferred Stock, reverse stock split, beneficial ownership limitations, Securities Purchase Agreement

4 terms

Series B-2 Preferred Stock financial

"The Reporting Person's 50 shares of Series B-2 Preferred Stock automatically converted"

reverse stock split financial

"Following the Issuer's subsequent reverse stock split, the conversion shares are reported"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

beneficial ownership limitations financial

"subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker"

Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.

Securities Purchase Agreement financial

"acquired pursuant to a Securities Purchase Agreement with the issuer, dated July 22, 2026"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dennis Matheis report for DarioHealth Corp. (DRIO) on July 23, 2026?

On July 23, 2026, director Dennis Matheis reported purchasing 14,430 shares of DarioHealth Common Stock. The shares were bought at $6.93 per share under a Securities Purchase Agreement dated July 22, 2026, and are held as a direct ownership position.

How many DarioHealth (DRIO) shares did Dennis Matheis buy and at what price?

Dennis Matheis bought 14,430 shares of DarioHealth Common Stock at a price of $6.93 per share. The purchase was completed pursuant to a Securities Purchase Agreement with the company dated July 22, 2026, and settled on July 23, 2026.

What was the nature of Dennis Matheis’s August 12, 2024 preferred stock conversion in DarioHealth (DRIO)?

On August 12, 2024, 50 shares of his Series B-2 Preferred Stock automatically converted into DarioHealth common stock. After a subsequent reverse stock split, the conversion is reported as 965 common shares, and he also received common shares under the preferred stock’s dividend provisions.

What beneficial ownership limitation applied to DarioHealth (DRIO) Series B Preferred Stock?

The Series B Preferred Stock carried beneficial ownership limitations, including a non-waivable 19.99% ownership blocker. Automatic conversion into common stock occurred on the 15‑month anniversary of issuance, but remained subject to this ownership cap to limit the holder’s percentage stake.

How many DarioHealth (DRIO) common shares did Dennis Matheis own after the August 12, 2024 conversion?

Immediately following the August 12, 2024 automatic conversion, Dennis Matheis beneficially owned 28,596 shares of DarioHealth Common Stock. This figure reflects the reverse stock split and includes common shares received both from the preferred share conversion and from applicable dividend provisions.

Was Dennis Matheis’s July 2026 DarioHealth (DRIO) purchase under a Rule 10b5-1 trading plan?

The report indicates the July 23, 2026 purchase of 14,430 shares at $6.93 per share was not effected pursuant to a Rule 10b5-1 trading plan. The associated Rule 10b5-1 checkbox for the filing was explicitly left unchecked.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 05:28 PM Accepted by SEC EDGAR 07/28/2026 - 05:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matheis Dennis

(Last) (First) (Middle)

322 W 57TH STREET, #33B

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DarioHealth Corp. [ DRIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2024

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2024(1)		C		965(2)	A	$19.1(2)	28,596(2)	D
Common Stock	07/23/2026(3)		P		14,430	A	$6.93	43,026	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B-2 Preferred Stock	$1,000	08/12/2024		C			50	05/04/2023	08/04/2024	Common Stock	965	$1,000	0	D

Explanation of Responses:

1. Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

2. The Reporting Person's 50 shares of Series B-2 Preferred Stock automatically converted into 19,289 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 965 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 28,596 shares of Common Stock immediately following the conversion.

3. The reported shares were acquired pursuant to a Securities Purchase Agreement with the issuer, dated July 22, 2026, at a purchase price of $6.93 per share.

	/s/ Dennis Matheis	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)